As one of the only independent partnering events dedicated to showcasing drug development programs that are ready for partnering or venture funding, the BIO Investor Forum 2024 focused on treating patients by accelerating the progress of new therapeutic technologies into commercialization.
A look back at BIO Investor Forum 2024
.jpeg)
.jpg)
Articles about BIO Investor Forum
BIO Investor Forum opens with encouraging news on financing
The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally.
While the volume of investment improved in the first half of 2024, much of it went to a few “mega deals,” leaving many promising small biotechs still seeking funding, according to data presented during the Oct. 15 opening panel of the 2024 BIO Investor Forum in San Francisco, hosted by the Biotechnology Innovation Organization (BIO).
BIO Investor Forum panel breaks down when, what, and why of IPOs
Biotech firms weighing an initial public offering (IPO) must consider timing, interest in their product, the macro environment—and whether they really need all the headaches, according to an Oct. 16 BIO Investor Forum panel.
“Why do you want to go public? It’s not a super-fun experience,” said Colin Walsh, Managing Director, Growth Equity at Goldman Sachs. “Being public has a whole different set of requirements and expectations which are pretty disconnected from biotech writ large,” including low investor tolerance for the setbacks that are common during drug development.
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}